The use of HSP90 inhibitors as monotherapy has brought about some successes, as well as instances in which tumor reduction only occurred when the HSP90 inhibitors were administered, returning after the inhibitors were withdrawn. The gene discussed is HSP90AB1; the disease is neoplasm.